AbbVie-allied ADARx aims for IPO with 3 drugs in the clinic
RNA interference company ADARx Pharmaceuticals revealed its intentions to go public in a Friday night SEC filing, trying to take advantage of the industry's IPO momentum. The San Diego biotech plans to list on the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.